

## **CS Pharmaceuticals announces appointment of Darren Mercer as Chief Executive Officer**

London, England, June 1, 2021, CS Pharmaceuticals Ltd. (CSP), a British speciality pharmaceutical company focused on first- and best-in-class speciality therapeutics and treatments for rare diseases in China, are pleased to announce the appointment of Darren Mercer as Chief Executive.

“We are delighted to have appointed Darren Mercer as Chief Executive Officer. Darren is a strategic leader with extensive international experience, gained in a number of senior roles. Prior to joining CS Pharmaceuticals, he was SVP Commercial at Circassia Pharmaceuticals, responsible for the Ex-US business and in particular the expansion of the business in China resulting in significant sales growth and reimbursement in a number of provinces for the lead product. Prior to joining Circassia he spent 10 years at Takeda Pharmaceuticals where he was Head of Commercial Operations, Asia Pacific” said Steve Harris, Chairman of CSP.

“I am delighted to be joining CSP at this exciting phase of the business. I have worked first-hand in China for many years and seen the need for a trusted partner operating to international standards of quality and compliance. With our offering of dedicated regulatory, market access, medical and commercial expertise, CSP is rapidly becoming a ‘go-to’ trusted licensing partner for companies wishing to develop and commercialize their products in China.” said Darren Mercer, CEO.

### **About CS Pharmaceuticals**

CS Pharmaceuticals (CSP) is a British multinational pharmaceutical company focused on licensing Chinese commercialisation rights to Western rare disease and speciality medicines. The company, with its headquarters in London and offices in Beijing, offers dedicated regulatory, market access, medical and commercial expertise, in addition to international-standard compliance and legal capabilities. The team has an impressive track record of success in China, providing partners with significant experience in this fast growing market. With its dedicated commercialisation platform, CSP is rapidly becoming a ‘go-to’ trusted licensing partner, expanding its portfolio of innovative rare disease and ophthalmology assets while making business easier for companies wishing to develop and commercialize their products in China.

[www.cspharmaceuticals.com](http://www.cspharmaceuticals.com)

### **Contacts**

CS Pharmaceuticals  
Darren Mercer, Chief Executive Officer

Tel: +44 (0) 2037 534691